Effect of the dwell time deviation constraint on brachytherapy treatment planning for cervical cancer.

Objective: This study aimed to quantify the effect of the dwell time deviation constraint (DTDC) on brachytherapy treatment for cervical cancer.

Methods: A retrospective study was carried out on 20 patients with radical cervical cancer. The DTDC values changed from 0.

Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer.

Purpose: Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) to inhibit tumor growth. Nimotuzumab has demonstrated desirable therapeutic activity in various types of tumors. However, the benefit of nimotuzumab for the treatment of cervical cancer is not entirely clear.

Distribution of circulating tumor cell phenotype in early cervical cancer.

Circulating tumor cells (CTCs) can be classified into three phenotypes based on epithelial-to-mesenchymal transition (EMT) markers, including epithelial CTCs, mesenchymal CTCs, and mixed phenotypic CTCs. This study is aimed to analyze the correlation between CTC phenotypes and the clinicopathological features of patients with early cervical cancer. Peripheral blood samples were obtained from 90 patients with early cervical cancer.

Postoperative chemoradiotherapy versus radiotherapy alone for cervical cancer: A systematic review and meta-analysis.

The aim of this study was to compare the treatment outcomes of postoperative chemoradiotherapy (CRT) with radiotherapy (RT) alone in patients with cervical cancer. Based on articles published up to December 2014 a literature search in PubMed and EMBASE was conducted to identify eligible studies. Risk ratio (RR) and its 95% confidence interval (CI) were used as pooled statistics.